Nutex Health (NASDAQ:NUTX) Director Purchases $14,034.00 in Stock

Nutex Health Inc. (NASDAQ:NUTX) Director Frank Jaumot acquired 150 shares of the stock in a transaction dated Friday, March 20th. The shares were bought at an average cost of $93.56 per share, for a total transaction of $14,034.00. Following the acquisition, the director owned 150 shares in the company, valued at $14,034. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Nutex Health Stock Performance

Shares of NUTX stock traded up $5.78 during trading on Monday, reaching $94.77. The company had a trading volume of 141,962 shares, compared to its average volume of 205,966. The firm’s 50 day simple moving average is $120.56 and its two-hundred day simple moving average is $125.28. Nutex Health Inc. has a one year low of $45.88 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.41 and a quick ratio of 3.39. The company has a market capitalization of $660.54 million, a PE ratio of 10.55 and a beta of 0.04.

Nutex Health (NASDAQ:NUTX) last announced its earnings results on Thursday, March 5th. The company reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). Nutex Health had a return on equity of 17.67% and a net margin of 7.34%.The company had revenue of $151.68 million for the quarter, compared to the consensus estimate of $258.82 million.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nutex Health in a report on Monday, December 29th. Wall Street Zen downgraded shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Saturday, March 7th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.50.

Institutional Trading of Nutex Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue bought a new position in Nutex Health in the 3rd quarter worth approximately $30,000. Islay Capital Management LLC acquired a new position in shares of Nutex Health during the fourth quarter worth approximately $34,000. BNP Paribas Financial Markets boosted its position in shares of Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock valued at $40,000 after acquiring an additional 290 shares during the period. Ameritas Investment Partners Inc. bought a new stake in shares of Nutex Health in the second quarter valued at approximately $44,000. Finally, Royal Bank of Canada grew its stake in shares of Nutex Health by 752.4% in the fourth quarter. Royal Bank of Canada now owns 358 shares of the company’s stock worth $59,000 after acquiring an additional 316 shares during the last quarter. Institutional investors and hedge funds own 5.32% of the company’s stock.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.